Two Sigma Advisers’s Praxis Precision Medicines PRAX Stock Holding History

Two Sigma Advisers’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,047	Closed	-$26.8K	–	2611
2023 Q3	$26.8K	Sell	1,047 -606	-37%	-$11.5K	﹤0.01%	2312
2023 Q2	$28.5K	Sell	1,653 -9,807	-86%	-$150K	﹤0.01%	2307
2023 Q1	$139K	Sell	11,460 -18,387	-62%	-$776K	﹤0.01%	2329
2022 Q4	$1.07M	Sell	29,847 -3,740	-11%	-$117K	﹤0.01%	1534
2022 Q3	$1.14M	Buy	33,587 +18,854	+128%	+$939K	﹤0.01%	1455
2022 Q2	$541K	Buy	14,733 +10,913	+286%	+$1.16M	﹤0.01%	1882
2022 Q1	$585K	Sell	3,820 -353	-8%	-$72.5K	﹤0.01%	1907
2021 Q4	$1.23M	Buy	4,173 +2,173	+109%	+$637K	﹤0.01%	1451
2021 Q3	$555K	Buy	2,000 +393	+24%	+$107K	﹤0.01%	1886
2021 Q2	$441K	Buy	+1,607	New	+$575K	﹤0.01%	1992

Other funds holding PRAX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Two Sigma Advisers's PRAX Position: Q4 2023 in Review

Two Sigma Advisers sold out of Praxis Precision Medicines (PRAX) in Q4 2023, closing a stake of 1,047 shares — an estimated $26.8K sold.

Two Sigma Advisers first reported a position in PRAX in Q2 2021 and held it in 10 quarters. The position peaked at $1.23M in Q4 2021. 60 funds tracked by Wall St. Rank hold PRAX as of Q4 2023.

Two Sigma Advisers reported no remaining Praxis Precision Medicines position as of Q4 2023 after selling out during the quarter.
Two Sigma Advisers sold 1,047 Praxis Precision Medicines shares in Q4 2023, an estimated $26.8K.
Two Sigma Advisers first reported a position in Praxis Precision Medicines in Q2 2021 and held it in 10 quarters.
Two Sigma Advisers's Praxis Precision Medicines position peaked at $1.23M in Q4 2021.
60 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2023.

Based on Two Sigma Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.